NCT00668031 - Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement | Biotech Hunter

Enrollment

359

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions

Blood Loss, Surgical

Interventions

DRUG

Trasylol (Aprotinin, BAYA0128)

A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump

DRUG

Placebo

A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump

Trial Locations (40)

19107

Philadelphia

21215

Baltimore

27401

Greensboro

27710

Durham

32250

Jacksonville Beach

33703

St. Petersburg

33744

Bay Pines

34239

Sarasota

35205

Birmingham

36608

Mobile

46158

Mooresville

46260

Indianapolis

48197

Ypsilanti

49009

Kalamazoo

75231

Dallas

78233

San Antonio

79410

Lubbock

80012

Aurora

83702

Boise

85023

Phoenix

92037

La Jolla

92123

San Diego

97701

Bend

06032

Farmington

52242-1089

Iowa City

01655

Worcester

15213-2592

Pittsburgh

T6G 2B7

Edmonton

V1Y 1T2

Kelowna

V6Z 1Y6

Vancouver

E3B 5N5

Fredericton

B3H 3A7

Halifax

N1E 4J4

Guelph

N2G 1G3

Kitchener

N6A 5A5

London

L1G 2B9

Oshawa

L1J 2J2

Oshawa

L4C 4Z3

Richmond Hill

G1L 3L5

Québec

00935

San Juan